You are here

Statements

The statements and guidelines EASD is involved in have significant visibility and have, particularly concerning statements on treatment and diagnostic criteria, substantial impact on health care politics.

Therefore, the Committee on Clinical Affairs (CCA) is responsible for structuring and overseeing EASD’s activities in the development of formal statements and guidelines.

Mission

The mission of the CCA is to ensure that any guideline or statement which is produced and/or endorsed by EASD is appropriate, non-contradictory and consistent with current research findings and best practice in diabetes management.

This supports the EASD mission of promoting excellence in diabetes care through research and education and the stated aims of the Association to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

Role

The role of CCA is to advise the EASD Board on all matters concerning guidelines and statements. The Committee will:

Evaluate all initial requests from members of the Association or other institutions or societies concerning the development of guidelines and statements and advise the Executive Committee accordingly.

Oversee all activities of the Association in the different guideline and statement committees and advise the Board accordingly.

Guidelines and Statements:

Glucose Management for Exercise using Continuous Glucose Monitoring (CGM) and Intermittently Scanned CGM (isCGM) Systems in Type 1 Diabetes – Position Statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA) (2020)

Precision medicine in diabetes. ADA and EASD Consensus Report (2020)

Diabetes digital app technology: benefits, challenges, and recommendations. EASD and ADA Diabetes Technology Working Group Consensus Report (2019)

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. ADA and EASD Cosensus Report (2019)

Management of hyperglycaemia in type 2 diabetes: ADA and EASD Consensus Report (2018)

2016 European Guidelines on CVD Prevention in Clinical Practice (2016)

EASL - EASD - EASO Clinical Practice Guidelines for management of non-alcoholic fatty liver disease (2016)

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015)

Insulin Pump Risks and Benefits: A Clinical Appraisal of Pump Safety Standards, Adverse Event Reporting, and Research Needs. A Joint EASD and ADA Statement (2015)

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2013)

ADA/EASD/IDF Recommendations for Clinicians and People with Diabetes Concerning the Use of Incretin Therapy and Pancreatic Disease (2013)

Medical Devices in Diabetes Care: A statement on behalf of the European Association for the Study of Diabetes (2013)

New WHO criteria on use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus (2011)

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) (2009)